Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 2/2020

16.01.2020 | Original Contributions

Combined antisclerostin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats

verfasst von: Jinti Lin, M.D., Jun Wu, M.D., Shuaibo Sun, M.D., Kai Chen, M.D., Hongqiang Wu, Renjin Lin, M.D., Chengwei Zhou, M.D., Jianzhong Kong, M.D., Kailiang Zhou, M.D., Xiaolong Shui, M.D.

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Osteoporotic bones heal more slowly and ineffectively than normal bones. A combination of antibodies against sclerosing protein (Scl-Ab), and parathyroid hormone 1–34 (PTH 1–34) may improve healing. A standard osteoporotic rat model was established 12 weeks after bilateral ovarian resection (OVX). Bone defects were created in the right femora of 80 rats, which were randomly divided into 4 groups: control, Scl-Ab (25 mg/kg twice weekly), PTH (60 μg/kg of PTH 1–34 three times a week) and PTH plus Scl-Ab. After 12 weeks of treatment the rats were sacrificed and blood and the distal femora were harvested for biochemical evaluation, histology, microcomputed tomography and biomechanical testing. Compared to the control group, monotherapy and combination therapy with PTH and/or Scl-Ab promoted the formation of new bone, enhanced maximum femoral loading and increased the levels of procollagen type I N‑terminal propeptide (PINP) and osteocalcin. The administration of PTH + Scl-Ab maximally enhanced bone defect healing. Combination treatment was better than either treatment alone, indicating a synergistic effect.
Literatur
1.
Zurück zum Zitat Andreassen TT, Fledelius C, Ejersted C, Oxlund H (2001) Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 72(3):304–307CrossRef Andreassen TT, Fledelius C, Ejersted C, Oxlund H (2001) Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 72(3):304–307CrossRef
2.
Zurück zum Zitat Bone HG, Greenspan SL, Mckeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85(2):720–726PubMed Bone HG, Greenspan SL, Mckeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85(2):720–726PubMed
3.
Zurück zum Zitat Comelekoglu U, Bagis S, Yalin S, Ogenler O, Yildiz A, Sahin NO, Oguz I, Hatungil R (2007) Biomechanical evaluation in osteoporosis: ovariectomized rat model. Clin Rheumatol 26(3):380–384CrossRef Comelekoglu U, Bagis S, Yalin S, Ogenler O, Yildiz A, Sahin NO, Oguz I, Hatungil R (2007) Biomechanical evaluation in osteoporosis: ovariectomized rat model. Clin Rheumatol 26(3):380–384CrossRef
4.
Zurück zum Zitat Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13(4):485–496CrossRef Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13(4):485–496CrossRef
5.
Zurück zum Zitat Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135(22):3801–3811CrossRef Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135(22):3801–3811CrossRef
6.
Zurück zum Zitat Merlotti D, Falchetti A, Chiodini I, Gennari L (2019) Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother 20(7):805CrossRef Merlotti D, Falchetti A, Chiodini I, Gennari L (2019) Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother 20(7):805CrossRef
7.
Zurück zum Zitat Komatsu DE, Mary MN, Jason SR, Robling AG, Turner CH, Warden SJ (2010) Modulation of Wnt signaling influences fracture repair. J Orthop Res 28(7):928–936PubMedPubMedCentral Komatsu DE, Mary MN, Jason SR, Robling AG, Turner CH, Warden SJ (2010) Modulation of Wnt signaling influences fracture repair. J Orthop Res 28(7):928–936PubMedPubMedCentral
8.
Zurück zum Zitat Komrakova M, Stuermer EK, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Daub F, Martens T, Witzenhausen P (2010) Effect of human parathyroid hormone hPTH (1–34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone 47(3):480–492CrossRef Komrakova M, Stuermer EK, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Daub F, Martens T, Witzenhausen P (2010) Effect of human parathyroid hormone hPTH (1–34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone 47(3):480–492CrossRef
9.
Zurück zum Zitat Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209CrossRef Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209CrossRef
10.
Zurück zum Zitat Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R (2009) Sclerostin antibody treatment increases bone formation, bone mass, and Bbone strength in a rat model of postmenopausal osteoporosis † ‡. J Bone Miner Res 24(4):578–588CrossRef Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R (2009) Sclerostin antibody treatment increases bone formation, bone mass, and Bbone strength in a rat model of postmenopausal osteoporosis † ‡. J Bone Miner Res 24(4):578–588CrossRef
11.
Zurück zum Zitat Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats † ‡. J Bone Miner Res 25(12):2647–2656CrossRef Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats † ‡. J Bone Miner Res 25(12):2647–2656CrossRef
12.
Zurück zum Zitat Meganck JA, Koh AJ, Keller ET (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42(4):806–818CrossRef Meganck JA, Koh AJ, Keller ET (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42(4):806–818CrossRef
13.
Zurück zum Zitat Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Ph DMYMD (2002) Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low-Dose Human Parathyroid Hormone (1–34) †. J Bone Miner Res 17(11):2038–2047CrossRef Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Ph DMYMD (2002) Mechanisms for the Enhancement of Fracture Healing in Rats Treated With Intermittent Low-Dose Human Parathyroid Hormone (1–34) †. J Bone Miner Res 17(11):2038–2047CrossRef
14.
Zurück zum Zitat Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42(1):90–97CrossRef Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42(1):90–97CrossRef
15.
Zurück zum Zitat Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones †. J Bone Miner Res 26(5):1012–1021CrossRef Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones †. J Bone Miner Res 26(5):1012–1021CrossRef
16.
Zurück zum Zitat Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25(5):948–959CrossRef Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25(5):948–959CrossRef
17.
Zurück zum Zitat Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26CrossRef Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19–26CrossRef
18.
19.
Zurück zum Zitat Tao ZS, Zhou WS, Tu KK, Huang ZL, Zhou Q, Sun T, Lv YX, Cui W, Yang L (2015) Effect exerted by Teriparatide upon Repair Function of beta-tricalcium phosphate to ovariectomised rat’s femoral metaphysis defect caused by osteoporosis. Injury 46(11):2134–2141CrossRef Tao ZS, Zhou WS, Tu KK, Huang ZL, Zhou Q, Sun T, Lv YX, Cui W, Yang L (2015) Effect exerted by Teriparatide upon Repair Function of beta-tricalcium phosphate to ovariectomised rat’s femoral metaphysis defect caused by osteoporosis. Injury 46(11):2134–2141CrossRef
20.
Zurück zum Zitat Tao ZS, Zhou WS, He XW, Liu W, Bai BL, Zhou Q, Huang ZL, Tu KK, Li H, Sun T, Lv YX, Cui W, Yang L (2016) A comparative study of zinc, magnesium, strontium-incorporated hydroxyapatite-coated titanium implants for osseointegration of osteopenic rats. Mater Sci Eng C Mater Biol Appl 62:226–232CrossRef Tao ZS, Zhou WS, He XW, Liu W, Bai BL, Zhou Q, Huang ZL, Tu KK, Li H, Sun T, Lv YX, Cui W, Yang L (2016) A comparative study of zinc, magnesium, strontium-incorporated hydroxyapatite-coated titanium implants for osseointegration of osteopenic rats. Mater Sci Eng C Mater Biol Appl 62:226–232CrossRef
21.
Zurück zum Zitat Tao ZS, Tu KK, Huang ZL, Zhou Q, Sun T, Xu HM, Zhou YL, Lv YX, Cui W, Yang L (2016) Combined treatment with parathyroid hormone (1–34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model. Med Biol Eng Comput 54(9):1353–1362CrossRef Tao ZS, Tu KK, Huang ZL, Zhou Q, Sun T, Xu HM, Zhou YL, Lv YX, Cui W, Yang L (2016) Combined treatment with parathyroid hormone (1–34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model. Med Biol Eng Comput 54(9):1353–1362CrossRef
22.
Zurück zum Zitat Zhang Y, Cheng N, Miron R, Shi B, Cheng X (2012) Delivery of PDGF‑B and BMP‑7 by mesoporous bioglass/silk fibrin scaffolds for the repair of osteoporotic defects. Biomaterials 33(28):6698–6708CrossRef Zhang Y, Cheng N, Miron R, Shi B, Cheng X (2012) Delivery of PDGF‑B and BMP‑7 by mesoporous bioglass/silk fibrin scaffolds for the repair of osteoporotic defects. Biomaterials 33(28):6698–6708CrossRef
23.
Zurück zum Zitat Tao ZS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T, Lv YX, Cui W, Yang L (2015) Treatment study of distal femur for parathyroid hormone (1–34) and Î2-tricalcium phosphate on bone formation in critical size defects in rats. J Biomater Appl 43(10):2136–2143 Tao ZS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T, Lv YX, Cui W, Yang L (2015) Treatment study of distal femur for parathyroid hormone (1–34) and Î2-tricalcium phosphate on bone formation in critical size defects in rats. J Biomater Appl 43(10):2136–2143
24.
Zurück zum Zitat Yao W, Dai W, Jiang L, Lay YA, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE (2015) Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 27(1):283–294CrossRef Yao W, Dai W, Jiang L, Lay YA, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE (2015) Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 27(1):283–294CrossRef
25.
Zurück zum Zitat Yang N, Cui Y, Tan J, Fu X, Han X, Leng H, Song C (2014) Local injection of a single dose of simvastatin augments osteoporotic bone mass in ovariectomized rats. J Bone Miner Metab 32(3):252–260CrossRef Yang N, Cui Y, Tan J, Fu X, Han X, Leng H, Song C (2014) Local injection of a single dose of simvastatin augments osteoporotic bone mass in ovariectomized rats. J Bone Miner Metab 32(3):252–260CrossRef
27.
Zurück zum Zitat Xiaoyan T, Jee WSS, Xiaodong L, Chris P, Zhu KH (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48(2):197–201CrossRef Xiaoyan T, Jee WSS, Xiaodong L, Chris P, Zhu KH (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48(2):197–201CrossRef
Metadaten
Titel
Combined antisclerostin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats
verfasst von
Jinti Lin, M.D.
Jun Wu, M.D.
Shuaibo Sun, M.D.
Kai Chen, M.D.
Hongqiang Wu
Renjin Lin, M.D.
Chengwei Zhou, M.D.
Jianzhong Kong, M.D.
Kailiang Zhou, M.D.
Xiaolong Shui, M.D.
Publikationsdatum
16.01.2020
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2020
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-019-01685-2

Weitere Artikel der Ausgabe 2/2020

Zeitschrift für Gerontologie und Geriatrie 2/2020 Zur Ausgabe

Journal Club

Journal Club

Mitteilungen der DGG

Mitteilungen der DGG

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.